Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Flumethovix is a combination topical medication containing fluocinonide, a synthetic glucocorticoid corticosteroid, and dimethicone, a silicone-based skin protectant[1]. Fluocinonide is a potent anti-inflammatory and immunosuppressive agent used to treat inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses such as psoriasis and atopic dermatitis[1]. Its mechanism of action involves binding to cytosolic glucocorticoid receptors, which leads to modulation of gene expression and suppression of pro-inflammatory mediators, ultimately reducing swelling, redness, and itching[1]. Dimethicone provides a protective barrier and helps retain skin moisture, alleviating dryness and irritation[1]. This combination is indicated for the management of inflammatory skin conditions, offering both anti-inflammatory effects and skin protection.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Flumethovix.